Alergia e Imunologia
Revisão sistemática | Fototerapia para eczema atópico.
3 Dez, 2021 | 10:54hPhototherapy for atopic eczema – Cochrane Library
Comentário no Twitter
New @CochraneSkin systematic review casts some light on the topic of visible #LightTherapy for treating atopic eczema – ( #eczema or #atopicdermatitis ) https://t.co/JsrQwdqMHr 32 studies, involving 1219 people included. pic.twitter.com/6SfmlA2kWZ
— Cochrane UK (@CochraneUK) November 6, 2021
Estudo de coorte | Condições alérgicas parecem estar relacionadas a menor risco de infecção por COVID-19.
1 Dez, 2021 | 15:32hComunicado de imprensa: Allergic conditions linked to lower COVID-19 infection risk – BMJ
Estudo original: Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK) – Thorax
Variante fortemente mutada do coronavírus põe os cientistas em alerta – “Pesquisadores estão correndo para determinar se uma variante de alta transmissibilidade na África do Sul é uma ameaça à efetividade das vacinas contra COVID.”
26 Nov, 2021 | 12:03hHeavily mutated coronavirus variant puts scientists on alert – Nature
Ver também:
Covid: New heavily mutated variant B.1.1.529 in South Africa raises concern – BBC
Scientists warn of new Covid variant with high number of mutations – The Guardian
South Africa detects new COVID variant with many mutations – MedicalXpress
Comentário relacionado no Twitter (fio – clique para saber mais)
THREAD on the new variant B.1.1.529 summarising what is known from the excellent South African Ministry of Health meeting earlier today
TLDR: So much uncertain but what *is* known is extremely worrying & (in my opinion) we should revise red list immediately.
This is why: 1/16
— Prof. Christina Pagel (@chrischirp) November 25, 2021
[Preprint] Respostas sorológicas ao reforço de vacina contra COVID-19 na Inglaterra.
26 Nov, 2021 | 11:56hSerological responses to COVID-19 booster vaccine in England – medRxiv
Comentário do autor no Twitter (fio – clique para saber mais)
1/ Our preprint on #SARSCoV2 antibody responses in UK adults receiving a #COVID19 vaccine booster with the Pfizer vaccine at least 6 months after primary immunisation with Pfizer or AZ vaccine, which was given at an extended interval (8-12 wks) … 🧵
— Shamez Ladhani (@ShamezLadhani) November 25, 2021
Estudo de coorte baseado na população do Catar mostrou que as reinfecções tiveram 90% menos chances de resultar em internação ou morte do que as infecções primárias.
25 Nov, 2021 | 15:18hConteúdo relacionado: [Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.
Relatório Clínico AAP | Biológicos para asma e doenças alérgicas cutâneas em crianças.
19 Nov, 2021 | 13:03hBiologics for Asthma and Allergic Skin Diseases in Children – Pediatrics
Estudo randomizado fase 4 | Administração de vacinas contra COVID-19 (AstraZeneca ou Pfizer) concomitantemente às vacinas contra influenza sazonal em adultos é segura e preserva a resposta imune de ambas as vacinas.
15 Nov, 2021 | 14:10hOpinião | Imunidade após recuperação de infecção por SARS-CoV-2.
10 Nov, 2021 | 12:48hProtective immunity after recovery from SARS-CoV-2 infection – The Lancet Infectious Diseases
Comentário no Twitter
"Policy makers should consider recovery from previous SARS-CoV-2 infection equal to immunity from vaccination for purposes related to entry to public events, businesses, and the workplace,or travel requirements"
Do you agree with this?
I don't #IDtwitter https://t.co/FHbgXILD8Z— Antibiotic Stewa®️x🆔 Bassam Ghanem (@ABsteward) November 9, 2021
Como as vacinas contra COVID baseadas em proteína podem mudar a pandemia.
9 Nov, 2021 | 12:19hHow protein-based COVID vaccines could change the pandemic – Nature
Sprays nasais, adesivos livres de agulhas, imunidade duradoura: a próxima geração de vacinas contra COVID.
9 Nov, 2021 | 12:18h